GleamWall
中文EN

CNTB Connect Biopharma Holdings Ltd

Pharmaceutical Preparations · Nasdaq · SEC CIK 1835268 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY382.0%
TTM net income YoY-37.9%
TTM EPS YoY-28.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-1,879.9%
Net margin-1,849.7%
FCF margin-1,504.2%
EBITDA margin-1,861.7%

Returns

ROE-201.5%
ROA-142.8%
ROIC (approx.)-834.2%
Asset turnover0.08x

Leverage & solvency

Liabilities / assets56.6%
Debt / equity0.00x
Current ratio1.49x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.81x
Accruals ratio-26.7%
Payout ratio—
Capex / revenue0.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$736,000$2.77M$169,000$0$16,000$48,000$0$698,000
R&D expense$12.79M$16.27M$15.03M$11.28M$11.11M$8.77M$6.63M$6.24M
SG&A expense$4.26M$4.10M$4.75M$4.24M$6.58M$4.70M$4.81M$4.08M
Operating income-$16.31M-$17.60M-$19.61M-$15.53M-$17.68M-$13.42M-$11.45M-$9.62M
Pretax income-$16.13M-$17.22M-$19.35M-$15.08M-$17.14M-$12.84M-$10.22M-$8.80M
Income tax$20,000$60,000$48,000$27,000$61,000$55,000$54,000$106,000
Net income-$16.15M-$17.28M-$19.40M-$15.11M-$17.20M-$12.90M-$10.27M-$8.91M
EBITDA-$16.15M-$17.44M-$19.44M-$15.35M-$17.50M-$13.25M-$11.27M-$9.46M
EPS (basic)-0.26-0.27-0.34—-0.31-0.23-0.19—
EPS (diluted)-0.26-0.27-0.34—-0.31-0.23-0.19—
Weighted avg. shares (diluted)62.97M62.88M56.55M—55.72M55.50M55.35M—
Balance sheet
Cash & equivalents$16.50M$27.02M$46.03M$38.34M$37.84M$40.63M$47.71M$78.23M
Short-term investments$2.99M$4.47M$0$6.00M$16.94M$31.14M$36.29M$15.48M
Receivables$788,000$2.94M$0$13,000$17,000$0$8,000$789,000
Current assets$23.14M$38.62M$55.02M$50.93M$62.60M$77.76M$87.75M$96.96M
PP&E, net$3.48M$3.60M$3.70M$3.81M$3.94M$4.05M$3.91M$4.05M
Intangibles$40,000$42,000$43,000$45,000$47,000$48,000$50,000$53,000
Total assets$27.77M$43.47M$60.07M$56.08M$67.36M$82.72M$92.69M$101.28M
Current liabilities$15.49M$16.30M$17.05M$13.61M$11.43M$10.74M$8.56M$8.46M
Total liabilities$15.71M$16.61M$17.44M$14.10M$11.99M$11.38M$9.79M$9.12M
Shareholders' equity$12.05M$26.86M$42.62M$41.98M$55.37M$71.34M$82.90M$92.17M
Shares outstanding62.99M62.97M62.71M56.44M55.79M55.58M55.35M55.35M
Cash flow statement
Operating cash flow-$12.05M-$15.92M-$16.00M-$11.25M-$17.41M-$12.59M-$9.96M-$2.32M
Capital expenditure$6,000$0$0$16,000$34,000$303,000$81,000$313,000
Free cash flow-$12.06M-$15.92M-$16.00M-$11.27M-$17.44M-$12.89M-$10.04M-$2.63M
Investing cash flow$1.49M-$4.47M$6.00M$10.98M$14.35M$5.13M-$20.64M-$15.76M
Financing cash flow$0$1.33M$17.62M$715,000$215,000$161,000$2,000$106,000
Depreciation & amortization$162,000$161,000$164,000$181,000$179,000$171,000$173,000$158,000
Stock-based compensation$1.26M$1.26M$1.20M$917,000$916,000$951,000$942,000$1.40M

Free plan shows the latest 8 periods; Pro shows all 11 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.